The round was led by Section 32, with participation from Refactor Capital and Verily.
The company will use the funds to expand its digital biomanufacturing platform and develop additional bioreactor facilities.
Led by CEO Will Patrick, Culture Biosciences is a biotechnology company advancing a biomanufacturing platform that enables companies to run, monitor and analyze bioreactor experiments from the cloud.
The platform, which integrates bioreactors, cloud monitoring capabilities and remote operations, is currently being used by biotechnology companies to optimize their R&D processes.
FinSMEs
12/02/2019